CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-13-15
Credit Expiration Date: August-13-16


Edouard Trabulsi, MD, FACS
Associate Professor of Urology
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
Course Chair
Arthur L. Burnett, MD, MBA
Patrick C. Walsh Distinguished Professor of Urology
Director, Basic Science Laboratory in Neurourology
Director, Sexual Medicine Fellowship Program
Faculty Member, Cellular and Molecular Medicine
Graduate Training Program
Johns Hopkins Medical Institutions
Baltimore, MD


Credit Hours



Online Presentation

Program Description

NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on April 22, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.

Among men in the United States, prostate cancer is the most common cancer and the second leading cause of cancer-related death. The recommended treatment options for prostate cancer vary based on disease severity and life expectancy, with traditional approaches including active surveillance, surgery, radiation therapy, and androgen deprivation therapy (ADT), also referred to as hormonal therapy. Prostate cancer that progresses despite ADT is indicated by a rise in prostate specific antigen (PSA) levels and is known as CRPC. Because most deaths from prostate cancer are due to CRPC, treatment of this form of prostate cancer is of critical importance. Recent advances in understanding the pathogenesis of CRPC have led to at least 6 new therapeutic strategies and increased optimism regarding the treatment of CRPC. This activity will address gaps in knowledge, skills, and competency of evidence-based treatment among oncology and urology clinicians.

• Introduction (2 minutes)
• Recent FDA approvals of new CRPC therapies (3 minutes)
• Investigational therapies in late stages of development (5 minutes)
• Recent updates to clinical practice guidelines (5 minutes)
• Prevention of skeletal-related events in CRPC (5 minutes)
• Systemic therapy for metastatic CRPC (5 minutes)
• Radiopharmaceutical therapy (5 minutes)
• Androgen-deprivation therapy (5 minutes)
• Chemotherapy/immunotherapy (5 minutes)
• Collaboration among urology and medical oncology (5 minutes)
• Conclusion (5 minutes)

Program Developer/Facilitator

Produced in collaboration with MCM Education.

Target Audience

Urologists, medical oncologists, radiation oncologists, and other clinicians interested and involved in the treatment of patients with prostate cancer. There are no prerequisites for this activity.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:

  1. Summarize recent updates to clinical practice guidelines that reflect significant changes in best practices in the management of CRPC.
  2. Describe evidence-based first- and second-line treatment regimens for CRPC.
  3. Summarize current data for investigational therapies for CRPC in late stages of clinical development.
  4. Discuss strategies to increase collaboration between urology and medical oncology clinicians.


As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Edouard Trabulsi, MD, FACS, has no conflicts of interest to disclose.

Course Chair Arthur L. Burnett, MD, MBA, discloses the following:
Consultant: Lilly; Reflexonic, LLC; Genomic Health, Inc.; Endo Pharmaceuticals
Research Support: American Medical Systems, LLC; Coloplast; Pfizer Inc; Auxilium Pharmaceuticals, Inc.; Acorda Therapeutics, Vivus, Inc

Wm. Kevin Kelly, DO, discloses the following:
Consultant: Sanofi U.S.

Christopher Amling, MD, FACS, has no conflicts of interest to disclose.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion: No off-label products discussed.

Credit Statements

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Commercial Support Statements

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and sanofi-aventis U.S.


Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

  1. Please turn off all pop-up blockers to ensure access to the educational activity.
  2. Click on the "Start program" icon at the bottom of this page. You may start as a GUEST, but to claim credit, you must be a member. If you are not already registered as a user of this website, visit the login/registration page where you will be able to register as a new member or check existing registration information.
  3. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
  4. After the program has finished, click on the "Post-test" button.
  5. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.

Certificate Fee



The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

© 2015 The Johns Hopkins University.

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.


I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-502-7983, e-mail:


The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is here for training, education and/or observation purposes only.
For CME Questions, please contact the CME Office
(410) 955-2959 or e-mail
For CME Certificates, please call (410) 502-9634

Johns Hopkins University School of Medicine Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195

Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu